Indegene Share Price

Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a digitalfirst life sciences commercialization company, enabling biopharmaceutical, emerging biotech, and medical device companies to develop, launch, and scale the impact of their products with greater speed and efficiency. As a specialized company, it combine healthcare domain expertise, fitforpurpose technology, and an agile operating model to solve the most complex problems in the healthcare industry.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH, a medical writing consultancy firm. It set up a new global delivery center in Hyderabad. In FY 2025, the Company launched a new center in Hyderabad to strengthen the business operations. In Europe, it launched a new entity in Spain and a new center in London. Indegenes Europebased clients became as a strategic hub for consulting and commercialization solutions and modernize their operations with an AIfirst approach. Further, the Company acquired MJL Life Sciences, a UKbased specialized healthcare advertising and communications agency. It launched Cortex, a fitforpurpose Generative AI platform for the life sciences industry.In FY202526, Company acquired BioPharm in October 2025, acquired Warn Co and Cake Kommunikations for global delivery in Europe.

For the full year FY2026–2027, revenue reached ₹3582.5 crore and profit touched at ₹401.1 crore.